ArticleLancet regional health. Americas2026
Trends and drivers of multidrug-resistant bacteria incidence in 59 Chilean intensive care units, 2015-2024: a Bayesian hierarchical analysis.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) is a major threat in intensive care units (ICUs). Evidence on determinants of multidrug-resistant (MDR) infections in ICUs remains limited. We aimed to assess temporal, institutional, and antibiotic-use drivers of MDR incidence across 59 Chilean ICUs across 40 hospitals (2015-2024). Methods: We conducted an ecological time-trend analysis using data from the Collaborative Group on Bacterial Resistance. MDR incidence density rates (IDRs) in 1000 patient-days comprised methicillin-resistant Findings: Between 2015 and 2024, MDR incidence declined by 21% (1.82-1.44 per 1000 patient-days), driven by reductions in CRPA (4.8-1.9), MRSA (3.2-1.0), and VRE (1.4-0.9). CRE declined modestly (2.7-1.7), while CPE increased from 0 to 1.3 after 2017. Adult ICUs and public hospitals had higher IDRs than paediatric and private units. In adjusted models, quinolone use was associated with higher MDR incidence (β = 0.08, 95% CI 0.03-0.14; p = 0.004), as was carbapenem use (β = 0.06, 0.03-0.09; p < 0.0001). Each additional hour of infectious disease specialist coverage per 100 bed-days reduced MDR incidence by ∼2% (β = -0.02, -0.03 to -0.01; p = 0.023). MRSA increased with quinolones, while CRE and CRPA increased with carbapenems. Interpretation: MDR incidence in Chilean ICUs remains high and driven by quinolone and carbapenem use. Strengthening AMS and specialist oversight, alongside stricter prescribing, could reduce burdens. Funding: No funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.